Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.45 |
| ▸ | GCGR | P47871 | 12/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | GCG | P01275 | 6/20 | 0.42 |
| ▸ | GLP1R | P43220 | 1/20 | 0.41 |
| ▸ | GIPR | P48546 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12648837 | 1.00 | SLC6A3 (0.47) | SLC6A3SLC6A9GCGRPPARGPPARA | |
| SCHEMBL2667191 | 0.87 | GCGR (0.57) | SLC6A3GCGRGCGGLP1RGIPR | |
| SCHEMBL1765578 | 0.85 | GCGR (0.51) | GCGRGCGGLP1RGIPR | |
| SCHEMBL9071967 | 0.85 | GCGR (0.51) | GCGRGCGGLP1RGIPR | |
| SCHEMBL9071995 | 0.85 | GCGR (0.51) | GCGRGCGGLP1RGIPR | |
| SCHEMBL1765460 | 0.77 | GCGR (0.47) | GCGRGCGGLP1RGIPR | |
| SCHEMBL2655751 | 0.77 | CA9 (0.47) | SLC6A3GCGRPPARGPPARAPTGES | |
| SCHEMBL1765173 | 0.76 | GCGR (0.54) | GCGRGCGGLP1RGIPR | |
| SCHEMBL1765694 | 0.75 | GCGR (0.56) | GCGRGCGGLP1R | |
| SCHEMBL1765323 | 0.73 | GCGR (0.60) | GCGRGCGGLP1RGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609892-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2013-12-17 | — | — | US | claimed |
| US-20110124648-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2011-05-26 | — | — | US | claimed |
| EP-2159221-A1 | Glucagon receptor antagonists, preparation and therapeutic uses | Eli Lilly & Company (US) | 2010-03-03 | — | — | EP | claimed |
| EP-1758853-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2010-01-20 | — | — | EP | claimed |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | US | claimed |
| EP-1758853-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2005123668-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-29 | — | — | WO | claimed |
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | REMD Biotherapeutics, Inc | 2017-05-25 | — | — | US | disclosed |
| US-8609892-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2013-12-17 | — | — | US | disclosed |
| US-20110124648-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100324140-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2010-12-23 | — | — | US | disclosed |
| US-7816557-B2 | 3-{4-[1-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-benzoylamino}-propionic acid; treat diabetic and other glucagon related metabolic disorders | ELI LILLY AND COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| EP-2159221-A1 | Glucagon receptor antagonists, preparation and therapeutic uses | Eli Lilly & Company (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-1758853-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1758853-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123668-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124648-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | GLP1R, GCGR, GIPR | SLC6A3 1907/4885SLC6A9 1708/4885GCGR 2/4885 |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | SLC6A3 1907/4885SLC6A9 1708/4885GCGR 2/4885 |
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | GLP1R, GCGR, GIPR | SLC6A3 3439/4885SLC6A9 3776/4885GCGR 2/4885 |
| US-20100324140-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | GLP1R, GCGR, GIPR | SLC6A3 1907/4885SLC6A9 1708/4885GCGR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.